NYSE:NVTA Invitae Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Invitae Co. Please log in to your account or sign up in order to add this asset to your watchlist. $2.83 -0.14 (-4.71%) (As of 07/6/2022 12:00 AM ET) Add Compare Share Today's Range$2.79▼$3.1350-Day Range$2.13▼$5.9652-Week Range$2.08▼$33.81Volume8.28 million shsAverage Volume10.17 million shsMarket Capitalization$648.89 millionP/E RatioN/ADividend YieldN/APrice Target$15.42 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Invitae MarketRank™ ForecastAnalyst RatingHold2.29 Rating ScoreUpside/Downside444.8% Upside$15.42 Price TargetShort InterestBearish21.93% of Shares Sold ShortDividend StrengthN/ASustainability-1.12Upright™ Environmental ScoreNews Sentiment0.15Based on 3 Articles This WeekInsider TradingSelling Shares$303,038 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($2.86) to ($2.46) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.2.05 out of 5 starsMedical Sector427th out of 1,433 stocksMedical Laboratories Industry12th out of 32 stocks 3.1 Analyst's Opinion Consensus RatingInvitae has received a consensus rating of Hold. The company's average rating score is 2.29, and is based on 3 buy ratings, 3 hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $15.42, Invitae has a forecasted upside of 444.8% from its current price of $2.83.Amount of Analyst CoverageInvitae has only been the subject of 4 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted21.93% of the outstanding shares of Invitae have been sold short.Short Interest Ratio / Days to CoverInvitae has a short interest ratio ("days to cover") of 5.9.Change versus previous monthShort interest in Invitae has recently increased by 13.47%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldInvitae does not currently pay a dividend.Dividend GrowthInvitae does not have a long track record of dividend growth. Previous Next 3.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreInvitae has received a 65.95% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Diagnostic test kits" and "Private genetic testing services" products. See details.Environmental SustainabilityThe Environmental Impact score for Invitae is -1.12. Previous Next 1.2 News and Social Media Coverage News SentimentInvitae has a news sentiment score of 0.15. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.87 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Invitae this week, compared to 3 articles on an average week.Social Mentions This WeekMarketBeat has tracked 1 reddit mention for Invitae this week, compared to 0 mentions on an average week.Search InterestOnly 124 people have searched for NVTA on MarketBeat in the last 30 days. This is a decrease of -19% compared to the previous 30 days.MarketBeat FollowsOnly 16 people have added Invitae to their MarketBeat watchlist in the last 30 days. This is a decrease of -45% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Invitae insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $303,038.00 in company stock.Percentage Held by InsidersOnly 1.90% of the stock of Invitae is held by insiders.Percentage Held by Institutions91.87% of the stock of Invitae is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Invitae are expected to grow in the coming year, from ($2.86) to ($2.46) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Invitae is -0.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Invitae is -0.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioInvitae has a P/B Ratio of 0.22. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive NVTA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Invitae and its competitors with MarketBeat's FREE daily newsletter. Email Address About Invitae (NYSE:NVTA) StockInvitae Corporation, a medical genetics company, integrates genetic information into mainstream medicine to improve healthcare of people in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, cardiology, neurology, pediatrics, oncology, metabolic conditions, and rare diseases; digital health solutions; and health data services. It serves patients, healthcare providers, biopharma companies, and other partners. The company was formerly known as Locus Development, Inc. and changed its name to Invitae Corporation in 2012. Invitae Corporation was incorporated in 2010 and is headquartered in San Francisco, California.Read More NVTA Stock News HeadlinesJuly 2, 2022 | fool.comBear Market or Not, You Shouldn't Inherit This Stock's Problems - The Motley FoolJuly 2, 2022 | nasdaq.comBear Market or Not, You Shouldn't Inherit This Stock's Problems - NasdaqJuly 7, 2022 | Investing Daily (Ad)27 U.S. Cities Where Stocks Yield 26% a YearWhat’s the highest-yielding stock you’ve ever owned? The dividends for these stocks have risen so fast over the years that they’re now yielding us an average of 26%! When you start getting paid 26% on your money, your financial problems tend to pretty much evaporate. July 2, 2022 | finance.yahoo.comBear Market or Not, You Shouldn't Inherit This Stock's ProblemsJune 29, 2022 | americanbankingnews.comInvitae (NYSE:NVTA) Shares Down 6.8% June 26, 2022 | americanbankingnews.comInvitae (NYSE:NVTA) Sees Strong Trading VolumeJune 23, 2022 | americanbankingnews.comBrokerages Set Invitae Co. (NYSE:NVTA) Price Target at $15.42June 22, 2022 | seekingalpha.comInvitae Stock: Coming Out Of The Cash Burn, Speculative Strong Buy (NYSE:NVTA) - Seeking AlphaJuly 7, 2022 | Investing Daily (Ad)27 U.S. Cities Where Stocks Yield 26% a YearWhat’s the highest-yielding stock you’ve ever owned? The dividends for these stocks have risen so fast over the years that they’re now yielding us an average of 26%! When you start getting paid 26% on your money, your financial problems tend to pretty much evaporate. June 20, 2022 | finance.yahoo.comSignify (SGFY) Stock Jumps 6%: Will It Continue to Soar? - Yahoo FinanceJune 16, 2022 | stocknews.comNVTA: 4 Genomics Stocks to Consider Buying After the Crash - StockNews.comJune 15, 2022 | americanbankingnews.comInvitae (NYSE:NVTA) Sets New 12-Month Low on Analyst DowngradeJune 14, 2022 | americanbankingnews.comInvitae (NYSE:NVTA) Given New $6.00 Price Target at BenchmarkJune 13, 2022 | finance.yahoo.comSURVIVEHER™ FOUNDER AND MULTIMEDIA PERSONALITY LYNDSAY LEVINGSTON SHARES HER POWERFUL STORY AS A BREAST CANCER SURVIVOR - Yahoo FinanceJune 3, 2022 | fool.comWhy Invitae Stock Plummeted by 15% Today - The Motley FoolJune 3, 2022 | finance.yahoo.comWhy Invitae Stock Plummeted by 15% TodayJune 3, 2022 | benzinga.comPiper Sandler Initiates Coverage On Invitae with Underweight Rating, Announces Price Target of $2.5 - Ben - BenzingaJune 1, 2022 | seekingalpha.comInvitae: Hype Train Crashed As We Warned Last Year (NYSE:NVTA) - Seeking AlphaMay 31, 2022 | fool.com3 Stocks Wall Street Thinks Could Triple Your Money or Better - The Motley FoolMay 26, 2022 | finance.yahoo.comNew Research Demonstrates Genetic Information Can Transform Cancer Care, Guidelines Remain a Barrier to Patient AccessMay 21, 2022 | nasdaq.comI Made Lots of Mistakes With My First Home Purchase. Here's Why I Don't Regret It - NasdaqMay 21, 2022 | nasdaq.comShopping for a Mortgage? Don't Make This Mistake - NasdaqMay 21, 2022 | fool.com3 Biotech Stocks With a Cash Pile Higher Than Their Valuations - The Motley FoolMay 19, 2022 | finance.yahoo.comInvitae Launches Expanded Pharmacogenomics Panel and Specialized Mental Health PanelMay 13, 2022 | benzinga.comInvitae Earnings Perspective: Return On Capital Employed - Benzinga - BenzingaMay 6, 2022 | benzinga.comRaymond James Maintains Outperform on Invitae, Lowers Price Target to $8.5 - Benzinga - BenzingaMay 5, 2022 | investorplace.comCathie Wood Just Bought More Invitae (NVTA) Stock. Here’s Why.See More Headlines Industry, Sector and Symbol Stock ExchangeNYSE Industry Medical laboratories Sub-IndustryN/A SectorMedical Current SymbolNYSE:NVTA CUSIPN/A CIK1501134 Webwww.invitae.com Phone(415) 374-7782FaxN/AEmployees3,000Year FoundedN/ACompany Calendar Last Earnings5/03/2022Today7/07/2022Next Earnings (Estimated)8/02/2022Fiscal Year End12/31/2022Price Target and Rating Average Stock Price Forecast$15.42 High Stock Price Forecast$25.00 Low Stock Price Forecast$6.00 Forecasted Upside/Downside+444.8%Consensus RatingHold Rating Score (0-4)2.28571428571429 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($3.25) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-379,010,000.00 Net Margins-148.62% Pretax Margin-107.46% Return on Equity-24.48% Return on Assets-14.35% Debt Debt-to-Equity Ratio0.56 Current Ratio6.14 Quick Ratio5.88 Sales & Book Value Annual Sales$460.45 million Price / Sales1.41 Cash FlowN/A Price / Cash FlowN/A Book Value$13.16 per share Price / Book0.22Miscellaneous Outstanding Shares229,290,000Free Float224,933,000Market Cap$648.89 million OptionableOptionable Beta2.03 Invitae Frequently Asked Questions Should I buy or sell Invitae stock right now? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Invitae in the last year. There are currently 1 sell rating, 3 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Invitae stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NVTA, but not buy additional shares or sell existing shares. View analyst ratings for Invitae or view top-rated stocks. What is Invitae's stock price forecast for 2022? 7 brokers have issued twelve-month price targets for Invitae's stock. Their NVTA stock forecasts range from $6.00 to $25.00. On average, they predict Invitae's stock price to reach $15.42 in the next twelve months. This suggests a possible upside of 444.8% from the stock's current price. View analysts' price targets for Invitae or view top-rated stocks among Wall Street analysts. How has Invitae's stock price performed in 2022? Invitae's stock was trading at $15.27 at the beginning of the year. Since then, NVTA shares have decreased by 81.5% and is now trading at $2.83. View the best growth stocks for 2022 here. When is Invitae's next earnings date? Invitae is scheduled to release its next quarterly earnings announcement on Tuesday, August 2nd 2022. View our earnings forecast for Invitae. How were Invitae's earnings last quarter? Invitae Co. (NYSE:NVTA) posted its quarterly earnings data on Tuesday, May, 3rd. The medical research company reported ($0.78) earnings per share for the quarter, missing analysts' consensus estimates of ($0.77) by $0.01. The medical research company earned $123.70 million during the quarter, compared to analysts' expectations of $129.31 million. Invitae had a negative net margin of 148.62% and a negative trailing twelve-month return on equity of 24.48%. The business's revenue for the quarter was up 19.4% on a year-over-year basis. During the same period last year, the company posted ($0.63) earnings per share. View Invitae's earnings history. What guidance has Invitae issued on next quarter's earnings? Invitae issued an update on its second quarter 2022 earnings guidance on Monday, May, 9th. The company provided EPS guidance of for the period. The company issued revenue guidance of $133.76 million-$139.57 million, compared to the consensus revenue estimate of $128.13 million. Who are Invitae's key executives? Invitae's management team includes the following people: Dr. Sean Emerson George Ph.D., Co-Founder, Pres, CEO & Director (Age 48, Pay $500.15k)Ms. Yafei Wen, Chief Financial Officer (Age 49, Pay $422.73k)Mr. Kenneth D. Knight, Chief Operating Officer (Age 61, Pay $1M)Mr. Thomas R. Brida, Gen. Counsel, Chief Compliance Officer & Sec. (Age 51, Pay $425k)Dr. Robert L. Nussbaum, Chief Medical Officer (Age 72, Pay $391.35k) (LinkedIn Profile)Ms. Shelly D. Guyer, Chief Sustainability Officer (Age 62, Pay $430.44k) (LinkedIn Profile)Mr. Robert F. Werner, Chief Accounting Officer & Principal Accounting Officer (Age 49)Mr. Karthik Suri, Chief Product & Technology OfficerMr. Jackson J. Finks C.F.A., CFA, Director of Investor Relations & Strategic Fin.Mr. Lee Bendekgey, Chief Policy Officer (Age 64) What is Sean George's approval rating as Invitae's CEO? 59 employees have rated Invitae CEO Sean George on Glassdoor.com. Sean George has an approval rating of 87% among Invitae's employees. Who are some of Invitae's key competitors? Some companies that are related to Invitae include Elekta AB (publ) (EKTAY), Fulgent Genetics (FLGT), Veracyte (VCYT), CareDx (CDNA), RadNet (RDNT), Castle Biosciences (CSTL), Viridian Therapeutics (VRDN), Burning Rock Biotech (BNR), DermTech (DMTK), Personalis (PSNL), Genetron (GTH), Celcuity (CELC), MDxHealth (MDXH), Biora Therapeutics (BIOR) and Progenity (PROG). View all of NVTA's competitors. What other stocks do shareholders of Invitae own? Based on aggregate information from My MarketBeat watchlists, some companies that other Invitae investors own include NVIDIA (NVDA), Square (SQ), Roku (ROKU), Tesla (TSLA), Alibaba Group (BABA), Trade Desk (TTD), Shopify (SHOP), Salesforce (CRM), Advanced Micro Devices (AMD) and Okta (OKTA). When did Invitae IPO? (NVTA) raised $76 million in an initial public offering on Thursday, February 12th 2015. The company issued 5,400,000 shares at $13.00-$15.00 per share. J.P. Morgan acted as the underwriter for the IPO and Cowen and Company and Leerink Partners were co-managers. What is Invitae's stock symbol? Invitae trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVTA." How do I buy shares of Invitae? Shares of NVTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Invitae's stock price today? One share of NVTA stock can currently be purchased for approximately $2.83. How much money does Invitae make? Invitae (NYSE:NVTA) has a market capitalization of $648.89 million and generates $460.45 million in revenue each year. The medical research company earns $-379,010,000.00 in net income (profit) each year or ($3.25) on an earnings per share basis. How many employees does Invitae have? Invitae employs 3,000 workers across the globe. How can I contact Invitae? Invitae's mailing address is 1400 16th Street, SAN FRANCISCO CA, 94103. The official website for Invitae is www.invitae.com. The medical research company can be reached via phone at (415) 374-7782 or via email at ir@invitae.com. This page (NYSE:NVTA) was last updated on 7/7/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here
